Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Molecular Diagnostics

• Publication date

  2016-05-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/14737159.2016.1188692PMID 27169329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS

  2017cited by this paper
• shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin.

  2016cited by this paper
• A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer

  2015cited by this paper
• miR-214 as a key hub that controls cancer networks: small player, multiple functions.

  2015cited by this paper
• Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer.

  2015cited by this paper
• The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.

  2015cited by this paper
• HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

  2015cited by this paper
• NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis

  2015cited by this paper
• Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells

  2015cited by this paper
• Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.

  2015cited by this paper
• Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

  2015cited by this paper
• MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer

  2015cited by this paper
• Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes

  2015cited by this paper
• Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

  2015influential reference
• The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer

  2014cited by this paper
• Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications.

  2014cited by this paper
• TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

  2014cited by this paper
• Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?

  2014influential reference
• Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner

  2014cited by this paper
• Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells

  2014cited by this paper
• An international assessment of ovarian cancer incidence and mortality.

  2013cited by this paper
• miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells

  2013cited by this paper
• Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

  2013cited by this paper
• Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer

  2013cited by this paper
• Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET

  2013cited by this paper
• Epigenetic Therapies as a Promising Strategy for Overcoming Chemoresistance in Epithelial Ovarian Cancer

  2013cited by this paper
• Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

  2013cited by this paper
• A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis

  2013cited by this paper
• Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.

  2013cited by this paper
• Prognostic Value of Cancer Stem Cell Marker Aldehyde Dehydrogenase in Ovarian Cancer: A Meta-Analysis

  2013cited by this paper
• Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

  2013cited by this paper
• [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].

  2012cited by this paper
• Abstract 5093: Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome

  2012cited by this paper
• Let‐7 modulates acquired resistance of ovarian cancer to Taxanes via IMP‐1‐mediated stabilization of multidrug resistance 1

  2012cited by this paper
• The tumor microenvironment is a dominant force in multidrug resistance.

  2012cited by this paper
• Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.

  2012influential reference
• Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin

  2012cited by this paper
• Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.

  2012cited by this paper
• Tumor endothelial markers as a target in cancer

  2012cited by this paper
• Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel

  2012cited by this paper
• Reversal of Paclitaxel Resistance in Epithelial Ovarian Carcinoma Cells by a MUC1 Aptamer-let-7i Chimera

  2012cited by this paper
• Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

  2011cited by this paper
• Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity.

  2011cited by this paper
• Molecular approaches to personalizing management of ovarian cancer.

  2011cited by this paper
• Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide

  2011cited by this paper
• Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile

  2011cited by this paper
• Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer

  2010cited by this paper
• Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma.

  2010cited by this paper
• SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.

  2010cited by this paper
• Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.

  2010cited by this paper
• Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics

  2010cited by this paper
• Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.

  2010cited by this paper
• Annexin A4 interacts with the NF-κB p50 subunit and modulates NF-κB transcriptional activity in a Ca2+-dependent manner

  2010cited by this paper
• Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

  2010cited by this paper
• MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents

  2009cited by this paper
• Is NF-κB a good target for cancer therapy? Hopes and pitfalls

  2009cited by this paper
• Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe

  2009cited by this paper
• Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

  2009cited by this paper
• Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.

  2009cited by this paper
• Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

  2009cited by this paper
• A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility

  2009cited by this paper
• Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

  2009cited by this paper
• Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin

  2009cited by this paper
• Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer

  2009cited by this paper
• Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.

  2008cited by this paper
• Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt

  2008cited by this paper
• Significance of Toll-like Receptors Expression in Tumor Growth and Spreading: A Short Review

  2008cited by this paper
• Role of microRNAs in drug-resistant ovarian cancer cells.

  2008cited by this paper
• MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.

  2008cited by this paper
• IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.

  2007cited by this paper
• An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

  2007cited by this paper
• Molecular targets on blood vessels for cancer therapies in clinical trials.

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease

  2007cited by this paper
• [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].

  2007cited by this paper
• Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin

  2006cited by this paper
• Targeting multidrug resistance in cancer

  2006cited by this paper
• Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer

  2006cited by this paper
• Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.

  2006cited by this paper
• The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein research

  2006influential reference
• Molecular profiling of platinum resistant ovarian cancer

  2006cited by this paper
• Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.

  2006cited by this paper
• Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.

  2006cited by this paper
• MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer

  2006cited by this paper
• Defeating drug resistance in cancer.

  2006cited by this paper
• Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.

  2005cited by this paper
• Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

  2005cited by this paper
• Aminopeptidase A is a functional target in angiogenic blood vessels.

  2004cited by this paper
• Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination.

  2004cited by this paper
• Tumor endothelial markers: new targets for cancer therapy

  2004cited by this paper
• Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis

  2004cited by this paper
• Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.

  2004cited by this paper
• Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy

  2004cited by this paper
• Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells

  2004cited by this paper
• Identification of a novel protein complex containing annexin A4, rabphilin and synaptotagmin

  2004cited by this paper
• BioMed Central Review

  2003cited by this paper
• Ovarian cancer: strategies for overcoming resistance to chemotherapy

  2003cited by this paper
• p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.

  2003cited by this paper

• The impact of MORC2 on glycolysis and the responsiveness of paclitaxel-resistant ovarian cancer cells

  2025cites this paper
• PTPN2 acts as a tumor suppressor and therapeutic target in ovarian cancer.

  2025cites this paper
• Clinical characteristics and predictors of survival in 284 patients with recurrent epithelial ovarian cancer: a large-scale retrospective analysis

  2025cites this paper
• Biosensors for cancer detection: A review

  2024cites this paper
• TQ-Ox, a novel synthetic derivative of thymoquinone on ovarian cancer cells in vitro

  2022cites this paper
• CMAR_A_291906 2389..2399

  2021cites this paper
• High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer

  2021cites this paper
• Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis

  2020cites this paper
• A Lab-on-a-Chip Device Integrated DNA Extraction and Solid Phase PCR Array for the Genotyping of High-Risk HPV in Clinical Samples

  2019cites this paper
• Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases

  2019influential citation
• HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity

  2019cites this paper
• Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF‐κB pathway

  2016cites this paper
• OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution

  2016cites this paper